NewKerala.com

Key Points

Mankind Pharma experienced a 10.7% net profit drop in Q4 FY25, despite robust revenue growth of 27.1%. The company maintained its leadership in prescription volumes and saw strong performance in chronic therapies and consumer healthcare segments. Integration costs and regulatory challenges impacted margins, which declined from 24.2% to 22.2%. Despite short-term challenges, management remains optimistic about long-term growth potential.

Key Points: Mankind Pharma Q4 Profit Drops 27% Despite Revenue Growth

  • Company's revenue rises 27.1% to Rs 3,079.4 crore
  • EBITDA grows 16.5% with margin pressures
  • Retained top pharma prescription ranking
  • Successful Bharat Serums and Vaccines integration
2 min read

Mankind Pharma's Q4 net profit drops 10.7 pc

Mankind Pharma reports Q4 net profit decline while expanding chronic therapies and consumer healthcare segments

"FY25 was a transformative year laying foundation for long-term sustainable growth - Rajeev Juneja, Vice Chairman & MD"

Mumbai, May 21

Mankind Pharma on Wednesday reported a 10.7 per cent year-on-year (YoY) decline in net profit to Rs 420.8 crore for the quarter ended March 2025 (Q4 FY25), down from Rs 471.2 crore in the same quarter last fiscal.

The drop in profit came even as the company delivered strong revenue growth and continued its expansion in chronic therapies and consumer healthcare.

The company’s revenue for the March quarter rose sharply by 27.1 per cent to Rs 3,079.4 crore, driven by consistent growth in chronic segments, rising demand in its consumer healthcare portfolio, and the integration of Bharat Serums and Vaccines (BSV), which Mankind acquired to strengthen its presence in gynaecology and super-specialty therapies.

While the company’s EBITDA grew 16.5 per cent to Rs 683.2 crore during the quarter, its margins declined.

The EBITDA margin dropped to 22.2 per cent from 24.2 per cent a year earlier period. This margin pressure was largely due to integration costs and ongoing regulatory challenges in the acute therapy segment.

For the full financial year FY25, Mankind reported total revenue of Rs 12,207 crore, up 19 per cent from the previous fiscal year (FY24).

Domestic sales contributed Rs 10,675 crore, while exports saw a sharp rise of 88 per cent, reaching Rs 1,532 crore.

Adjusted EBITDA margin for the year stood at 25.9 per cent.

Mankind Pharma Vice Chairman and Managing Director Rajeev Juneja said the fourth quarter showed continued strong performance in chronic therapies, growing momentum in the consumer health segment, and successful progress in integrating BSV.

He described FY25 as a transformative year for the company, laying a foundation for long-term sustainable growth.

Mankind also retained its position as the top pharmaceutical company in India by prescription count for the eighth year in a row.

Its consumer brands, such as Manforce, Gas-O-Fast, and HealthOK, saw double-digit growth.

Shares of Mankind Pharma ended slightly lower at Rs 2,533.05 on the Bombay Stock Exchange (BSE), down 0.69 per cent.

- IANS

Share this article:

Reader Comments

R
Rahul K.
The profit drop is concerning but understandable given the BSV acquisition costs. Mankind has always been a reliable Indian pharma company - their chronic therapy focus shows good long-term vision. Hope they maintain their quality standards while expanding. 🇮🇳
P
Priya M.
Their consumer brands like Gas-O-Fast are household names now! The 88% export growth is impressive - shows Indian pharma's global potential. Margins will improve once BSV integration completes. Long term investors shouldn't worry about one quarter's numbers.
A
Amit S.
As someone who uses their diabetes medicines, I appreciate Mankind keeping prices reasonable despite inflation. Their prescription leadership for 8 years shows doctors trust them. Hope they don't compromise on affordability while chasing profits.
S
Sanjay V.
The market reaction seems overdone - stock down just 0.69% shows investors understand this is temporary. Their chronic therapy focus is smart as India's lifestyle diseases rise. More Indian companies should think long-term like Mankind.
N
Neha R.
While the numbers look good overall, I'm concerned about the margin pressure. Hope the BSV acquisition delivers promised synergies soon. Mankind should also focus more on R&D - we need Indian pharma to innovate, not just manufacture generics.
V
Vikram P.
Their consumer healthcare growth is impressive! Manforce condoms and Gas-O-Fast are market leaders. Shows how pharma companies can build strong OTC brands in India. The quarterly dip is just noise - this remains one of our best homegrown pharma stories. 💊

We welcome thoughtful discussions from our readers. Please keep comments respectful and on-topic.

Leave a Comment

Minimum 50 characters 0/50